On September 22, 2023 Incurix reported that its development substance ‘ICX-301’, a transcription factor targeting treatment for castration-resistant prostate cancer (CRPC), was selected as the second national candidate for 2023 by the National New Drug Development Project (Director Muk Hyun-sang) (Press release, Incurix, SEP 22, 2023, View Source;idx=93&page=1&code=news [SID1234643589]). It was announced on the 22nd that it was selected as a project to study the establishment of a new drug R&D ecosystem for the new drug development project.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
According to Incurix, castration-resistant prostate cancer develops within 13 to 30 months, depending on the progression of general prostate cancer. It is known that the expression of the AR mutation ‘AR splice variant-7’ (AR-V7) during the AR-DNA binding process causes drug resistance, low response rates to existing anticancer drugs, repeated recurrences, and ultimately leads to death. Incurix explains that prostate cancer has a large unmet need for which existing anticancer drugs can only extend survival in the short term.
‘ICX-301’ is a small molecule compound designed to address the unmet needs of castration-resistant prostate cancer. It is designed to inhibit the expression of transcription factors through direct inhibition of DNA binding at the site where the androgen receptor (AR) and mutant AR-V7 can bind.
Through this national new drug development project, Incurix will begin developing transcription factor-targeted treatments that not only have drug resistance but also have fewer side effects due to MOA (Mechanism of The Action) specificity over the next two years. The goal is to optimize the lead substances already secured and ultimately derive candidate substances that can enter non-clinical research.
Incurix is a company specializing in the development of new targeted anticancer drugs. It was founded by Kyeong-Chae Jeong, a senior researcher at the National Cancer Center, who has conducted research on the development of direct transcription factor inhibitors for 20 years. We are currently developing small molecule targeted anti-cancer drugs and have a pipeline targeting direct inhibition of c-Myc, STAT3, and AR transcription factors.
The National New Drug Development Project is a pan-ministerial national R&D (research and development) project to strengthen the global competitiveness of the domestic pharmaceutical and bio industry. For 10 years from 2021, we will support the entire cycle of new drug development with the goal of strengthening the domestic R&D ecosystem for new drug development, creating global commercialization results, and creating public outcomes in the health and medical field.